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A B S T R A C T
The aim of this study was to determine the incidence of monosymptomatic optic neuritis (MON) and progression of
MON to multiple sclerosis (MS) from the Mediterranean region of southern Europe in the County of Split-Dalmatia,
Croatia during the 11 years period from 1991 to 2001. This study was made retrospectively on the 87 cases (59 female,
aged 25.9±11.3 and 28 male aged 29.9±9.2) of MON, which were treated at the Department of Ophthalmology and De-
partment of Neurology, Split, University Hospital, from January 1991 to December 2001. In each case the diagnosis was
confirmed by a chart review and cases were ascribed to the data of admittance at hospital. The annual incidence of MON
was 1.9 per 100,000 (95% CI, 0.4–3.5). The incidence among males was 1.2 (95% CI, 0–2.9) cases / 100,000 per year and
2.5 (95% CI, 0.1–4.9) among females. A significant seasonal variations in the incidence of MON was not found (c2=6.81,
p=0.08). MS developed in 20 of 87 patients (22.9%) and median time was 25 (SE 8) months, (95% CI, 9–41) after the
MON onset. After two years 12.6% of patients with MON developed MS, 20.6% after 5 years and 22.9% after 10 years. MS
was slightly but not significantly more frequent in women than in men (c2 =0.72, p=0.3). In conclusion, the progression
of MON to MS in the County of Split-Dalmatia, Croatia was at a relatively moderate frequency.
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Introduction
Monosymptomatic optic neuritis (MON) often refers
to the acute disease of the optic nerve caused by any in-
flammatory optic neuropathy1–3. It typically manifests as
sudden monocular visual loss accompanied by eye pain in
young adults, with women more commonly affected than
men1–3. MON may be associated with a variety of sys-
temic autoimmune disorders, but the most common form
is acute demyelinating MON best known for its associa-
tion with multiple sclerosis (MS)1–5. Alternatively, the ep-
isode of MON may turn out to be an isolated and self-lim-
ited monophasic syndrome which will not go on to MS.
The new diagnostic criteria for MS proposed by the
American academy of neurology has been published re-
cently7. The rate of conversion to MS is not exactly deter-
mined and studies report rates from 11.5% to 85%, but
averages around 60%4–6,8–12. For MON brain magnetic
resonance imaging (MRI) lesions, oligoclonal bands or
intratectal IgG in cerebrospinal fluid (CSF) and female
sex are at higher risk of development of MS, while no
brain MRI lesions and normal CSF has a low-risk pro-
file7,10–14. In the Optic Neuritis Treatment Trial (ONTT)
the risk of MS within 10 years after the first episode of
MON was 56% among patients with one or more charac-
teristic white-matter lesions at baseline, as compared
with 22% among patients with no lesions10.
Abnormal brain MRI or CSF consistent with MS has a
positive predictive value for MS in the 80% to 90% ran-
ge13,14. A difference in the rate of conversion to MS is likely
to be due to number factors: study design, criteria of pa-
tient selection, length of follow-up and method of survey.
MON is regarded as a good marker of MS risk. Long
term observation showed that the majority of the MON
patients progressed to clinically definite MS4,10–11
The aim of this study was to determine the incidence
of MON and investigate the progression of MON to MS
in the County of Split-Dalmatia, the southern part of
Croatia during a 11 year period from 1991 to 2001.
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Materials and Methods
We retrospectively reviewed the charts of 87 patients
(59 female, aged 25.9±11.3 and 28 male aged 29.9±9.2)
who presented with MON. All patients were treated at
the Department of Ophthalmology and Department of
Neurology, Split, University Hospital, from January 1991
to December 2001. In every patient the diagnosis was
confirmed by a chart review and patients were ascribed
to the data of onset of symptoms rather than the data of
admittance at hospital. The criteria for entry into the
study included a diagnosis of acute optic neuritis with de-
creased and non-correctable visual acuity of eight days or
less, age between 18 and 46 years, no history of optic
neuritis or ophthalmoscopic signs of optic atrophy in the
affected eye, visual field loss, impaired color vision and a
relative afferent pupillary defect. Patients with identified
causes of optic nerve neuropathy such as infections in ad-
jacent regions, previous treatment with corticosteroids
for optic neuritis in the other eye, systemic diseases, reti-
nal or other intraocular pathology with symptoms mim-
icking those of MON were excluded. At study entry the
patients underwent ocular examinations including visual
acuity, color vision testing, visual field testing (with the
Goldmann perimeter), visual evoked potentials and stan-
dardized neurologic examinations. At the time of MON
onset the Poser criteria were used to exclude MS15. In
brief, patients with clinically definite MS (CDMS) in-
cluded two attacks and clinical evidence of two separate
lesions (CDMS1) or two attacks and clinical evidence of
one lesion and paraclinical evidence of another separate
lesion (CDMS2); patients with laboratory – supported de-
finitive (LSDMS) and patients with clinically probable MS
(CPMS) were excluded. Treatment of MON mainly con-
sisted of oral prednisone (1mg/kg), retrobulbar dexameth-
asone and since 1998 high-dose intravenous methypred-
nisolone. The high-dose intravenous methyprednisolone
produce short-term reduction in the rate of development
MS11.
Detailed history and physical examination at baseline
and follow period were performed. Follow-up neurologic
and ocular examinations were performed after 3 months
and 12 months and then yearly. The diagnosis of MS is
based on longitudinal clinical and brain MRI acquired
from the patients in the follow-up period. The character-
istic demyelinating lesions were defined by its size (greater
than or less than 3 mm), location (periventricular or
nonperiventricular) and shape (ovoid or nonovoid). Pa-
tients were were instructed to report any new or worsen-
ing of preexisting symptoms.
Four patients were lost to clinical follow-up, having
changed their address or refused further visit. The fol-
low-up periods ranged from 64 to 132 months (mean 108
months). Disability was recorded with the Kurzke ex-
panded disability status scale (EDSS)16.
Population data for the County of Split-Dalmatia were
based on the findings of the 2001 Croatia census and to-
tal population was 463,67617. Statistical analysis was
performed using c2 test and descriptive statistics using
statistical package for computer (Statistica for Windows
6.0, StatSoft.Inc. Tulsa, USA). Confidence intervals (CIs)
for incidence and relative risk (RR) were calculated at
the level 95%18.
Time to diagnosis of MS was evaluated by the Kaplan-
-Meier method. The log-rank test was used to compare
differences between the prognostic variables considered.
Incidence rates were adjusted to the age and sex distribu-
tion using the European Standard Population19.
Results
During the 11-year period from 1991 through 2001,
87 cases of MON were diagnosed among residents in the
County of Split-Dalmatia. 83 cases of MON were unilat-
eral and 4 cases had bilateral involvement. 59 (67.8%) of
the 87 patients were women and 28 (32.1%) men. The
mean age at onset of MON was 25.9 years (SD 11.3) for
females, and 29.9 years (SD 9.2) for males.
The annual incidence was 1.9 per 100.000 (95% CI,
0.4–3.5). The age and sex-specific incidence of MON is
presented in Table 1. The incidence among males was 1.2
(95% CI, 0–2.9) cases / 100,000 per year and 2.5 (95% CI,
0.1–4.9) among females. The corresponding age-adjusted
incidences were 1.3 per 100,000 person-years, 0.8 for
male and 1.8 for females. Although the difference in inci-
dence rates for women vs men was not significant, the
relative risk (RR) for women was 1.4 (95% CI, 0.4–6.6).
The peak incidence in both sexes observed in the group
20–29 years of age was 4.9 (95% CI, 0–11.4). RR of 20–29
years of age was 2.5 (95% CI, 1.4–4.3) compared with
0–19 years old group. Median visual acuity on the admis-
sion at hospital was 0.09 (range, 0.01–1.0). Median visual
acuity 6 months after the attack of MON was 0.8 (range,
0.1–1.0).
A significant seasonal variations in the incidence of
MON was not found (c=6.81, p=0.08). The seasons in
this calculations were; spring (March, April, May), sum-
mer (June, July, August), autumn (September, October,
November), winter (December, January, February). MS
developed in 20 of 87 patients (22.9%) and median time
to diagnosis of MS of entire MON population evaluated
by the Kaplan-Meier method was 25 (SE 8) months, (95%
CI, 9–41), Figure 1. After two years 12.6% of patients
with MON developed MS, 20.6% after 5 years and 22.9%
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TABLE 1
AGE AND SEX-SPECIFIC INCIDENCE OF OPTIC NEURITIS
AMONG COUNTY OF SPLIT-DALMATIA RESIDENTS, 1991
THROUGH 2001
Age Group, y Men Women Total
0–19 0.4 (0–2.7) 3.7 (3.2–10.6) 2 (0–5.9)
20–29 3.3 (0–10.5) 6.8 (0–10.4) 4.9 (0–11.4)
30–39 3.1 (0–10.4) 2.6 (0–9.7) 2.8 (0–7.8)
> 40 0.3 (0–1.5) 0.7 (0–2.6) 0.5 (0–1.6)
* Values are given as incidence per 100,000 person per year (95%
confidence interval).
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after 10 years. MS was slightly but not significantly more
frequent in women than in men (c2=0.72, p=0.3).
Discussion
A large number of studies have assessed the risk of de-
velopment of MS after an isolated episode of MON4–6,8–12.
The variations in the risk of development of MS are
mainly relates to differences in criteria for diagnosis of
MON and MS and in length of follow-up4,10–12. The risk of
MS steadily rises during the first 2 to 5 years following
MON, but than increase more gradually. According to the
review by Kurtzke, the risk ranges from 10% to 64% after
10 years3. In the ONTT the overall risk for development
of MS after an initially isolated episode of MON was 30%
at 5 year and 38% at 10-year follow-up10,11. It is interest-
ing to note that in our study although the MS was more
frequent in women than men, a significant difference
was not found. MS has been reported to be most likely to
develop within the first 2 to 5 years following acute
MON10–11. The risk calculated in our study confirmed
that MS usually occurs within the first 2–5 years with
median time of 25 months to diagnosis of MS. The overall
rate of progression of MON to MS in County of Split-
-Dalmatia after 5 and 10 years was generally lower than
in other studies. Rodrigez et al. found the risk for MS
was 39% after 10 years8. Kinnunen found by life time ta-
ble analysis that the probability of developing MS after 9
years was 36%20. In the study of Soderstorm et al. the cal-
culation risk was 36% after 2.1 years and in the study of
Ghezzi et al. the observed risk was 30% at 4 years21–22.
The ONTT findings have shown that the proportion of
patients who developed MS continued to increase with
the length of follow-up 10–12. In the Optic Neuritis Study
Group, the recurrences of MON were more frequent in
patients with MS and most patients retained good visi-
on12. The most potent predictor of MS was the presence
of white matter lesions on the baseline MRI scan of the
brain10. The presence of such one lesion at least 3 mm in
diameter more than double the 10- years risk of MS10. In
our study at baseline the Poser criteria were used to ex-
clude MS15 and therefore is likely that the risk of devel-
oping MS could have been higher in our patients, if brain
MRI had been done at study enrollment.
In our study the highest incidence of MON was found
in the 20–29 age group and male to female ratio was 1.6.
Although in our study the difference in incidence rates
for women vs men was not significant (p=0.08), the rela-
tive risk for women was 1.4.This may be explained with
relatively small cases of MON in our study, and in statis-
tically non-significant differences. In the County of Split-
-Dalmatia, there is no private hospital or places that take
care of MON except this hospital. It is still possible that
some cases may have been unregistered; some cases may
have been recognized and treated in other hospital in
Croatia.
The recent report from 10-year follow-up from the
Optic Neuritis Study Group cohort provides valuable MS
prognostic informations23. Most patients who develop
MS following an initial MON will have a relatively be-
nign course for at least 10 years23.
In conclusion, although this study has been made ret-
rospectively with a relatively small number of cases
treated at the end of the observed period (1998–2001)
with high-dose intravenous methyprednisolone and with-
out brain MRI performed at the beginning of the study, it
shows that progression of MON to MS in the County of
Split-Dalmatia is relatively moderate.
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Fig. 1. Kaplan-Meier analysis of the cumulative probability of time
to diagnosis of MS of entire MON population.
U:\coll-antropolo\coll-antro-2-2007\Bojic-5071.vp
12. lipanj 2007 13:48:09
Color profile: Disabled
Composite  150 lpi at 45 degrees
atia, Zagreb, 2003). — 18. GARDNER MJ, ALTMAN DG, Calculating con-
fidence intervals for proportions and their differences. In: GARDNER
MJ, ALTMAN DG (Eds), Statistics with Confidence Intervals and Statis-
tical Guidelines (BMJ, London, 1989). — 19. United Nations Population
Division. World population prospect: the 2002 revision population data-
base, Available from: http://esa.un.org/unpp/index.asp?panel=2, accessed:
December 5, 2003. — 20. KINNUNEN E, Acta Neurol Scand, 68 (1983)
371. — 21. SODERSTROM M, YA-PING J, HILLERT JLINK II, Neurol-
ogy, 50 (1998) 708. — 22. GHEZZI A, MARTINELLI V, TORRI V, ZAF-
FAARONI M, RODEGHER M, COMI G, J Neurol, 246 (1999) 770. — 23.
Optic Neuritis Study Group, Arch Neurol, 61 (2004) 1386.
L. Boji}
Department of Ophthalmology, University Hospital »Split«, Spin~i}eva 1, 21000 Split, Croatia
e-mail: lovreb@kbsplit.hr
PROGRESIJA OPTI^KOG NEURITISA U MULTIPLU SKLEROZU U SPLITSKO-DALMATINSKOJ
@UPANIJI, HRVATSKA
S A @ E T A K
Cilj ovog ispitivanja je bio odrediti incidenciju monosimptomatskog opti~kog neuritisa (MON) i njegovu progresiju u
multiplu sklerozu (MS) u mediteranskom dijelu ju`ne Europe,u Hrvatskoj, @upaniji splitsko-dalmatinskoj, u 11 go-
di{njem razdoblju od 1991 do 2001. godine. Ovo retrospektivno ispitivanje je u~injeno kod 87 bolesnika (59 `ena u dobi
od 25,9±11,3 god. i 28 mu{karca u dobi od 29,9±9,2 god.) lije~enih od MON-a u Klinici za o~ne bolesti i Klinici za
neurologiju, Klini~ke Bolnice Split od sije~nja 1991. do prosinca 2001. godine. Kod svakog bolesnika dijagnoza je po-
tvr|ena uvidom u povijesti bolesti, a bolesnici su razvstani po datumu prijema u bolnicu. Godi{nja incidencija je bila 1.9
na 100.000 stanovnika (95% CI, 0,4–3,5). Incidencija me|u mu{karcima je bila 1,2 (95% CI, 0–2,9) slu~aja na 100,000
stanovnika na godinu i 2,5 (95% CI, 0,1–4,9) me|u `enama. Zna~ajne sezonske razlike u incidenciji MON-a nisu na|ene
(c²=6,81, p=0,08). MS se razvila u 20 od 87 bolesnika (22,9%) sa medianom vremena od 25 (SE 8) mjeseci, (95% CI,
9–41) od pojave MON-a. Tijekom prve dvije godine od nastanka MON-a, od MS-e je obolilo 12,6% bolesnika, 20,6%
poslije pet godina i 22,9% poslije deset godina. MS je bila neznatno, ali ne i zna~ajnije ~e{}a kod `ena nego kod mu{karaca
(c²=0,72, p=0,3). U zaklju~ku, rizik od razvoja MS-e nakon MON-a u Hrvatskoj, u @upaniji splitsko-dalmatinskoj,
relativno je umjeren.
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